GAD-2 Administration and Interpretation
The GAD-2 should be administered by asking patients two questions about the past two weeks, with a positive screen defined as a score of ≥3 points, which has a sensitivity of 68% and specificity of 86% for detecting generalized anxiety disorder. 1
How to Administer the GAD-2
The GAD-2 consists of the first two questions from the GAD-7 scale. Ask patients: "Over the past two weeks, how often have you been bothered by the following problems?" 1
The two questions are:
- Feeling nervous, anxious, or on edge
- Not being able to stop or control worrying
Scoring for each question:
- Not at all = 0 points
- Several days = 1 point
- More than half the days = 2 points
- Nearly every day = 3 points
Add the scores from both questions to get the total GAD-2 score (range: 0-6 points).
Interpretation and Cut-off Scores
A score of ≥3 is considered a positive screen and indicates the need for further evaluation with the full GAD-7 or clinical interview. 1
Performance Characteristics at ≥3 Cut-off:
- Sensitivity: 68% (59-75% across studies) 2
- Specificity: 86% (82-89% across studies) 2
- Positive Predictive Value: 56% (assuming 20% pretest probability) 1
- Negative Predictive Value: 96% 1
- Positive Likelihood Ratio: 5.1 1
- Negative Likelihood Ratio: 0.17 1
Alternative Cut-off Consideration:
If you prioritize sensitivity over specificity (e.g., in high-risk populations where missing cases is more concerning), consider using a cut-off of ≥2, which provides:
This lower threshold is particularly useful when the clinical consequence of missing anxiety is high, though it will generate more false positives requiring further evaluation.
Clinical Context and Next Steps
When GAD-2 is positive (≥3): Proceed to full GAD-7 assessment or structured clinical interview to confirm diagnosis and assess severity. The GAD-2 is a screening tool, not a diagnostic instrument. 1
When GAD-2 is negative (<3): Anxiety disorder is unlikely (96% negative predictive value), but remain alert to clinical presentation, particularly in patients with somatic complaints or frequent healthcare visits. 1
Important Caveats
The GAD-2 performs better for detecting generalized anxiety disorder specifically than for other anxiety disorders (panic disorder, social phobia). For panic disorder, the sensitivity drops to 47% and specificity to 94% at the ≥3 cut-off. 1 If you suspect other anxiety disorders based on clinical presentation, proceed directly to more comprehensive assessment rather than relying solely on GAD-2.
The GAD-2 has been validated primarily for generalized anxiety disorder screening. Recent systematic review data shows moderate overall accuracy (AUC 0.82) for GAD detection, but lower accuracy (AUC 0.77) for any anxiety disorder. 2 Use caution when attempting to screen for anxiety disorders other than GAD. 5
Setting matters: The GAD-2 performs differently across clinical contexts. Sensitivity tends to be higher and specificity lower in patients with specific medical conditions (epilepsy, cancer, cardiovascular disease, multiple sclerosis) compared to general primary care populations. 2, 3, 6, 4 In specialized populations like MS patients, a ≥3 cut-off maintains excellent specificity (92%) with good sensitivity (87%). 4
Practical Implementation
The GAD-2 can be administered efficiently during intake encounters in primary care or obstetric offices, either on touchscreen devices or paper forms. 7 The brevity of the tool (two questions, <1 minute to complete) makes it ideal for busy clinical settings where comprehensive screening might otherwise be skipped. 7, 1
Screen routinely in high-risk populations: Women (lifetime prevalence 40%), adolescents (median onset age 11 years), pregnant and postpartum women, patients with depression (56% have comorbid anxiety), and those with frequent unexplained somatic complaints. 7
Always rule out alternative causes of anxiety symptoms before diagnosing an anxiety disorder, including thyroid disease, substance use, and medication effects. 7